Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors

Advances in Therapy

Volumn 32, Issue 6, 2015, Pages 510-522

  Rolfo, Christian ^a   Swaisland, Helen ^b   Leunen, Karin ^c   Rutten, Annemie ^d   Soetekouw, Patricia ^e   Slater, Sarah ^f   Verheul, Henk M W ^g   Fielding, Anitra ^h   So, Karen ^h   Bannister, Wendy ⁱ   Dean, Emma ^j  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Therakin Consulting   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ASTRAZENECA   (United Kingdom)

ⁱ PHASTAR   (United Kingdom)

^j CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

Food effect; Olaparib; Olaparib capsule; PARP inhibition; Pharmacokinetics; PK; Poly(ADP ribose) polymerase (PARP) inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN C; OLAPARIB; ANTINEOPLASTIC AGENT; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CALORIE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EVALUATION STUDY; FAT CONTENT; FATIGUE; FEMALE; FOOD; FOOD INTAKE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPOKALEMIA; HYPOTENSION; INTESTINE OBSTRUCTION; KLEBSIELLA INFECTION; LIMB PAIN; LIPID DIET; LUNG EMBOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; OPEN STUDY; PERIPHERAL EDEMA; PERITONITIS; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION; AGED; CLINICAL TRIAL; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; MIDDLE AGED; NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CROSS-OVER STUDIES; FEMALE; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL ABSORPTION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHTHALAZINES; PIPERAZINES;

EID: 84933680163     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0214-4     Document Type: Article

References (14)

1. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.
2. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852–61.
3. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245–51.
4. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–44.
5. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–61.
6. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation. J Clin Oncol. 2015;33:244–50.
7. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34.
8. European Medicines Agency. Lynparza (olaparib); EPAR summary for the public; EMA/662514/2014; EMEA/H/C/003726. EMA: London; 2015. http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/003726/human_med_001831.jsp. Accessed 18 May 2015.
9. U.S. Food and Drug Administration. Olaparib; 2014. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427598.htm. Accessed 18 May 2015.
10. AstraZeneca. Global Policy: Bioethics. 2015. http://www.astrazeneca.com/Responsibility/Code-policies-standards/Our-global-policies. Accessed 18 May 2015.
11. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry-Food-Effect Bioavailability and Fed Bioequivalence Studies. Rockville: FDA; 2002. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdf. Accessed 18 May 2015.
12. Gupta A, Moreno V, Dean EJ, et al. Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: dose-escalation phase. J Clin Oncol. 2012;30(15 Suppl):Abstract 3051.
13. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. NIH Publication No. 09-5410. Bethesda: NIH; 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 20 May 2015.
14. Molife LR, Forster MD, Krebs M, et al. A Phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors. J Clin Oncol. 2010;28(15 Suppl):Abstract 2599.